American International Group, Inc. Nuvation Bio Inc. Transaction History

American International Group, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.46 - $3.97 $900 - $2,449	-617 Reduced 0.85%	71,794 $261,000
Q4 2023 Feb 13, 2024	SELL	$0.96 - $1.53 $280 - $446	-292 Reduced 0.4%	72,411 $109,000
Q3 2023 Nov 13, 2023	BUY	$1.26 - $2.1 $3,257 - $5,428	2,585 Added 3.69%	72,703 $97,000
Q2 2023 Aug 04, 2023	BUY	$1.56 - $1.84 $21,747 - $25,651	13,941 Added 24.82%	70,118 $126,000
Q1 2023 May 12, 2023	BUY	$1.6 - $2.48 $1,788 - $2,772	1,118 Added 2.03%	56,177 $93,000
Q4 2022 Feb 10, 2023	SELL	$1.68 - $2.5 $336 - $500	-200 Reduced 0.36%	55,059 $105,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $226 - $3,155	781 Added 1.43%	55,259 $124,000
Q2 2022 Aug 12, 2022	SELL	$3.24 - $5.85 $79,201 - $143,003	-24,445 Reduced 30.97%	54,478 $177,000
Q1 2022 May 13, 2022	SELL	$4.6 - $8.83 $25,552 - $49,050	-5,555 Reduced 6.58%	78,923 $415,000
Q4 2021 Feb 11, 2022	BUY	$7.75 - $10.05 $371,690 - $481,998	47,960 Added 131.33%	84,478 $718,000
Q3 2021 Nov 12, 2021	BUY	$7.78 - $10.0 $129,692 - $166,700	16,670 Added 83.99%	36,518 $363,000
Q2 2021 Aug 13, 2021	BUY	$9.22 - $14.48 $182,998 - $287,399	19,848 New	19,848 $185,000

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $508M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.